BLA 761082: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761082's history or Kashiv BioSciences, LLC's company page.
On Aug 2, 2021, FDA declined to approve BLA 761082 (BLA 761082) from Kashiv BioSciences, LLC in its present form, citing facility inspections, product quality. The application was later approved.
- Letter date: Aug 2, 2021
- Application: BLA 761082
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA1. Aninspection of the Kashiv Biosciences LLC DS manufacture facility (FEI 3011289655), Chicago, Illinois, is required before this application can be approved as the FDA must assess the ability of that facility to conduct the listed manufacturing operations in...… openFDA did not return the full text just now. Open it in the letter search.
Other Letters on This Application
- TheragrastimDec 22, 2020 · BLA 761082 · later approved
- TheragrastimJun 11, 2019 · BLA 761082 · later approved
- BLA 761082May 10, 2018 · BLA 761082 · later approved
Kashiv BioSciences, LLC's Other Letters
Newest first- TPI-120Aug 11, 2021 · BLA 761084 · later approved
Record
- Company
- Kashiv BioSciences, LLC
- Application
- BLA 761082
- Status in openFDA
- Approved
- Review division
- Division of Nonmalignant Hematology
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters